NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma

Fei Lu,Yanan Zhao,Yihua Pang,Min Ji,Yanping Sun,Hongchun Wang,Jie Zou,Yan Wang,Guosheng Li,Tao Sun,Jingxin Li,Daoxin Ma,Jingjing Ye,Chunyan Ji
DOI: https://doi.org/10.1016/j.canlet.2020.10.024
IF: 9.756
2021-01-01
Cancer Letters
Abstract:<p>The NLRP3 inflammasome plays a pro-tumorigenic role in various malignancies. However, its potential role in lymphomagenesis remains unclear. In this study, we identified an immunosuppressive state in patients with diffuse large B cell lymphoma (DLBCL), which was characterized by markedly elevated interleukin (IL)-18 levels in lymphoma tissues and positive correlation with programmed death ligand 1 (PD-L1) expression. Furthermore, NLRP3 inflammasome activation in DLBCL cell lines upregulated PD-L1 and reduced the proportion of cytotoxic T cells. NLRP3 inflammasome blockade <em>in vivo</em> suppressed lymphoma growth and ameliorated anti-tumor immunity by downregulating PD-L1 in the tumor microenvironment and decreasing the proportion of PD-1/TIM-3-expressing T cells, myeloid-derived suppressor cells, tumor-associated macrophages, and regulatory T cells. Further <em>in vivo</em> studies revealed IL-18 as the main effector cytokine involved in the negative regulation of anti-lymphoma immunity. Interestingly, NLRP3 blockers combined with anti-PD-L1 treatment exerted antagonistic effects during lymphoma therapy. Altogether, our findings indicate that NLRP3 inflammasome promotes immunosuppression by modulating PD-L1 and immune cells. Accordingly, this study highlights the prognostic and therapeutic values of the NLRP3 inflammasome in lymphoma.</p>
oncology
What problem does this paper attempt to address?